---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Immune checkpoint inhibitors"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Immune checkpoint inhibitors. Topics: FDA-approved indication: pembrolizumab as a single agent, Recommended dosage in BCG-unresponsive high-risk NMIBC, KEYNOTE-057 Cohort A: design and population, KEYNOTE-057 Cohort A: efficacy in the prescribing information, and 5 further topics. 9 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description/immune-checkpoint-inhibitors"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Immune checkpoint inhibitors

<a id="heading-2.2.2.1.6"></a>

## 2.2.2.1.6 Immune Checkpoint Inhibitors

<a id="topic-2.2.2.1.6-1"></a>

### FDA-approved indication: pembrolizumab as a single agent

> “KEYTRUDA, as a single agent, is indicated for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.6-2"></a>

### Recommended dosage in BCG-unresponsive high-risk NMIBC

| Item | Pembrolizumab |
| --- | --- |
| Dose | “200 mg every 3 weeks or 400 mg every 6 weeks” |
| Duration | “Until persistent or recurrent high-risk NMIBC, disease progression, unacceptable toxicity, or up to 24 months” |

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.6-3"></a>

### KEYNOTE-057 Cohort A: design and population

> “The safety of KEYTRUDA was investigated in KEYNOTE-057, a multicenter, open-label, single-arm trial that enrolled 148 patients with high-risk non-muscle invasive bladder cancer (NMIBC), 96 of whom had BCG-unresponsive carcinoma in situ (CIS) with or without papillary tumors.”
> “Patients received KEYTRUDA 200 mg every 3 weeks until unacceptable toxicity, persistent or recurrent high-risk NMIBC, or progressive disease.”
> “The major efficacy outcome measures were complete response (as defined by negative results for cystoscopy [with TURBT/biopsies as applicable], urine cytology, and computed tomography urography [CTU] imaging) and duration of response.”
> “The study population characteristics were: median age of 73 years (range: 44 to 92); 44% age ≥75; 84% male; 67% White; and 73% and 27% with an ECOG performance status of 0 or 1, respectively.”
> “Tumor pattern at study entry was CIS with T1 (13%), CIS with high grade TA (25%), and CIS (63%).”
> “The median follow-up time was 28.0 months (range: 4.6 to 40.5 months).”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.6-4"></a>

### KEYNOTE-057 Cohort A: efficacy in the prescribing information

| Endpoint | Pembrolizumab 200 mg every 3 weeks |
| --- | --- |
| Participants | “n=96” |
| Complete response rate (95% CI) | “41% (31, 51)” |
| Median duration of response, months (range) | “16.2 (0.0+, 30.4+)” |
| Duration of response ≥12 months, % (n) | “46% (18)” |
| Basis of duration of response | “Based on patients (n=39) that achieved a complete response” |

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.6-5"></a>

### KEYNOTE-057 Cohort A: primary publication

> “In cohort A of the trial, adults aged 18 years or older with histologically confirmed BCG-unresponsive carcinoma in situ of the bladder, with or without papillary tumours, with an Eastern Cooperative Oncology Group performance status of 0-2, and who were ineligible for or declined radical cystectomy were enrolled.”
> “The primary endpoint was clinical complete response rate (absence of high-risk non-muscle-invasive bladder cancer or progressive disease), assessed by cystoscopy and urine cytology approximately 3 months after the first dose of study drug.”
> “Median follow-up was 36·4 months (IQR 32·0-40·7).”
> “39 (41%; 95% CI 30·7-51·1) of 96 patients with BCG-unresponsive carcinoma in situ of the bladder with or without papillary tumours had a complete response at 3 months.”
> “Grade 3 or 4 treatment-related adverse events occurred in 13 (13%) patients; the most common were arthralgia (in two [2%] patients) and hyponatraemia (in three [3%] patients).”

Source: [Balar et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34051177/)

<a id="topic-2.2.2.1.6-6"></a>

### KEYNOTE-057 Cohort B: papillary-only disease

> “Cohort B eligible patients were aged 18 years and older, had an Eastern Cooperative Oncology Group performance status of 0-2, and had BCG-unresponsive high-risk non-muscle-invasive bladder cancer with papillary tumours (high-grade Ta or any-grade T1) without carcinoma in situ.”
> “Primary endpoint was 12-month disease-free survival of high-risk non-muscle-invasive bladder cancer or progressive disease as assessed by cystoscopy, cytology, and central pathology and radiology review.”
> “The 12-month disease-free survival was 43·5% (95% CI 34·9-51·9).”
> “Treatment-related adverse events occurred in 97 (73%) of 132 patients; 19 (14%) had a grade 3 or 4 treatment-related adverse event; the most common grade 3 or 4 treatment-related adverse events were colitis (in three [2%] patients) and diarrhoea (in two [2%]).”
> “Findings will need to be confirmed in a randomised controlled trial.”

Source: [Necchi et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38740030/)

<a id="topic-2.2.2.1.6-7"></a>

### Safety in KEYNOTE-057

> “The median duration of exposure to KEYTRUDA was 4.3 months (range: 1 day to 25.6 months).”
> “KEYTRUDA was discontinued due to adverse reactions in 11% of patients.”
> “Serious adverse reactions occurred in 28% of KEYTRUDA-treated patients.”
> “The most frequent serious adverse reactions (≥2%) in KEYTRUDA-treated patients were pneumonia (3%), cardiac ischemia (2%), colitis (2%), pulmonary embolism (2%), sepsis (2%), and urinary tract infection (2%).”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.6-8"></a>

### FDA advisory committee review of KEYNOTE-057

> “In KEYNOTE-057, the CRR at first disease assessment was 41% (95% CI: 31%, 51%) and median DOR was 16.2 months; 46% of responders remaining in response for at least 1 year.”
> “The committee voted 9–4 in favor of a favorable benefit-risk profile for these patients.”

Source: [Heiss et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12363661/)

<a id="topic-2.2.2.1.6-9"></a>

### Other checkpoint inhibitors: atezolizumab in SWOG S1605

> “Notably, 3-month CR rates of 41% and 43% have been reported for pembrolizumab and atezolizumab, respectively, as monotherapy in patients with BCG-unresponsive CIS.”

Source: [Daneshmand et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12622271/)

> “In the SWOG S1605 phase II trial, atezolizumab only achieved a 27% CRR at six months in a cohort of 74 patients with CIS, with a median duration of response of 17 months not reaching the prespecified efficacy threshold.”

Source: [European Association of Urology NMIBC Guidelines (2026)](https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-2026.pdf)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
